Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Journal of Naval General Hospital of PLA》 2002-02
Add to Favorite Get Latest Update

Analysis on Treatment Results of 121 Patients with Primary Liver Carcinoma

JI Zhen hua, ZHANG Zhi cheng, BAI Gang, et al (Department of Hepatobiliary Surgery, Naval General Hospital, Beijing 100037, China)\;  
Objective To find the best protocol from analyzing therapeutic effect and significance of different methods for primary liver carcinoma.Methods 121 patients with primary liver carcinoma treated in 1991.5~1998.5 were divided into 4 groups: Conservative treatment group (A): only treated by oral chemotherapy, Chinese traditional medicine and hepatic function support; Chemoembolization group (B): taking 1~7 times hepatic arterial chemoembolization (HACE); Hepatic resection group (C): taking hepatic segmentectomy or lobectomy; Hepatic resection+chemotherapy group (D): taking HACE or portal vein infusion (PVI) or hepatic artery infusion (HAI) before or after hepatic segmentectomy or lobectomy. 57 patients treated by HACE were also divided into 4 groups: One time HACE (B 1); Two times HACE(B 2); Over three times HACE(B 3); HACE+other methods(B 4).Results The median survival period of 37 cases with early stage primary liver carcinoma was 24.0 months. Their survival rates in 1 ,2 and 3 year was 67.6%, 55.9%, 44.1% respectively. The median survival period of 87 cases with advanced primary liver carcinoma was 2.5, 8.0, 7.0 and 10.0 months in group A, B, C, D respectively. Their survival rates in 1 , 2 and 3 year was 8.3%, 0, 0 in group A; 28.1%, 10.5%, 7.0% in group B; 25.0%, 12.5%, 0 in group C; 50.0%, 10.0%, 10.0% in group D respectively. The survival rates differed significantly between 4 groups. Their survival rates in 1 , 2 and 3 year of 57cases treated by HACE was: 0, 0, 0 in group B 1; 37.5%, 12.5% 6.3% in group B 2; 35.5%, 11.8%, 5.9% in group B 3; 28.6%, 14.3%, 14.3% in group B 4 respectively. The survival rates differed significantly between B 1 and B 2, B 3, B 4. The survival rate in 3 year differed significantly between B 4 and B 1, B 2, B 3. Conclusion Surgical resection combined with local hepatic chemotherapy or chemoembolization significantly improves the curative effect and life quality of the patient with primary liver carcinoma. The best protocol of HACE is 2~3 times and with other adjuvant therapy.\;
【CateGory Index】: R735.7
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
【Co-citations】
Chinese Journal Full-text Database 10 Hits
1 SUN Xiao, FAN Hong-wei,YIN Zhong-pu (Nanyang Central Hospital,Nanyang 473009,China);Clinical Analysis on the Treatment of Primary Hepatic Carcinoma with Portal Vein Tumor Thrombi with Transcatherter Arterial Embolization[J];Henan Journal of Oncology;2003-02
2 Zhang Kaitai;Han Benli;Wang Yuzhi;(Department of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University,Chongqing 400038,China Academy of Military Medical Sciences, Beijing 100071,China);Molecular mechanism for effects of NM23-H1 on primary hepatocellular carcinoma with intrahepatic metastasis[J];中国人民解放军军医大学学报(英文版);1998-04
3 LEI Kefeng WANG Yanfang ZHU Xiaoqun et al Liver Cancer Institute,Zhongshan Hospital,Fudan University,Shanghai 200032;PGL1,a Candidate Metastatic Suppressor Gene of Human Hepatocellular Carcinoma[J];Chinese Journal of Clinical Medicine;2006-01
4 JIN Wen-jian1,CHEN Huo-guo1,HONG Dao-xian1,ZHANG Kun-he2(1.Fourth Department of Internal Medicine,Jiangxi Tumor Hospital,Nanchang 330029,China;2.Department of Gastroenterology,the First AffiliatedHospital of Jiangxi Medical College,Nanchang 330006,China);Relationship between Expression of E-cadherin and p120-catenin and Clinicopathological Features in Human Hepatocellular Carcinoma[J];Journal of Nanchang University(Medical Science);2010-10
5 CAI Xin-ran,HUANG Chang-yu,ZHOU Liang-yi,et al.(Department of Hepatobiliary Surgery,Union Hospital,Fujian Medical University,Fuzhou,350001,China);Investigation of risk factors and therapy effection for different recurrent stage after resection of hepatocellular carcinoma[J];Journal of Practical Oncology;2010-05
6 绞? 杨继震;肝细胞癌转移的研究进展[J];WORLD CHINESE JOURNAL OF DIGESTOLOGY;1999-09
7 LI Qiang, HAO Xishan, ZHANG Zhongguo, et al. Cancer Hospital, Tianjin Medical University, Tianjin 300060, P. R. China;Clinical value of portal vein chemotherapy in treatment of hepatocellular carcinoma with tumor thrombosis of main trunk of portal vein[J];Chinese Journal of Hepatobiliary Surgery;2002-07
8 MENG Xiao-chun SHAN Hong ZHU Kang-shun ZHANG Jian-sheng WANG Xiao-hong QIN Jie GU Hui-zhen Department of Radiology,the Third Affiliated Hospital of Sun Yat-Sen University,Guangzhou 510630,China;The clinical significance of CT angiography in the diagnosis of arterioportal shunts associated with hepatocellular carcinoma[J];Chinese Journal of Radiology;2006-09
9 FAN Jia, WU Zhiquan, ZHOU Jian, et al. Zhongshan Hospital & Liver Cancer Institute, Shanghai Medical University, Shanghai 200032, China;Comparison of several therapeutic methods for hepatocellular carcinoma with tumor thrombi in portal vein[J];CHINESE JOURNAL OF ONCOLOGY;2000-03
10 HUANG Huarong.Department of Hepatobiliary Surgery,Huizhou Central Hospital,Guangdong,516001,China;The effect of c-mycon hepatic apopotosis in hepatocelluler carcinoma after transcather arterial chemoembolization[J];Chinese Journal of Primary Medicine Pharmacy;2004-03
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved